U.S. PHARMACOPEIA

Search USP29  
Cefotetan
Click to View Image
C17H17N7O8S4 575.62

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)-thio]methyl]-8-oxo-, [6R-(6,7)]-.

(6R,7S)-4-[[2-Carboxy-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]carbamoyl]-1,3-dithietane-D2,-malonamic acid.

(6R,7S)-7-[4-(Carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid [69712-56-7].
» Cefotetan contains not less than 950 µg and not more than 1030 µg of cefotetan (C17H17N7O8S4) per mg, calculated on the anhydrous basis.
Packaging and storage— Preserve in tight containers.
Labeling— Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.
Identification—
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that observed in the chromatogram of the Standard preparation obtained as directed in the Assay.
Water, Method I 921: not more than 2.5%.
Sterility 71 (where it is labeled as sterile)— It meets the requirements when tested as directed for Membrane Filtration under Test for Sterility of the Product to be Examined, except to use Fluid A to each 1000 mL of which has been added 10 g of sodium bicarbonate before sterilization.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Other requirements— Where the label states that Cefotetan is sterile or must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements for Bacterial endotoxins under Cefotetan for Injection.
Assay— [NOTE—Protect the Standard preparation, the Resolution solution, and the Assay preparation from light, and use within 2 hours.]
Mobile phase— Prepare a filtered and degassed mixture of 0.1 M phosphoric acid, methanol, acetonitrile, and glacial acetic acid (1700:105:105:100). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Transfer about 20 mg of USP Cefotetan RS, accurately weighed, to a 100-mL volumetric flask, add 5 mL of methanol, swirl for several minutes, add 5 mL of acetonitrile, and swirl until dissolved. Dilute with water to volume, and mix.
Resolution solution— Place 10 mL of Standard preparation in a glass-stoppered flask containing a few mg of magnesium carbonate, and sonicate for 10 minutes. If the solution is not turbid, add a few more mg of magnesium carbonate, and repeat the sonication. Filter the turbid solution through a filter of 0.5 µm or finer porosity. Collect the clear filtrate, and use as the Resolution solution.
Assay preparation— Using a suitable quantity of Cefotetan, accurately weighed, proceed as directed for Standard preparation.
Chromatographic system (see Chromatography 621)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L1. The flow rate is about 2 mL per minute. Chromatograph 20 µL of the Resolution solution, and record the peak responses as directed for Procedure: the relative retention times are about 0.75 for cefotetan and 1.0 for cefotetan tautomer; and the resolution between the cefotetan peak and the cefotetan tautomer peak is not less than 2.0. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency is not less than 1500 theoretical plates, the tailing factor is not more than 1.5, and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas of the responses for the major peaks. Calculate the quantity, in µg, of cefotetan (C17H17N7O8S4) in each mg of the Cefotetan taken by the formula:
200(CP / M)(rU / rS),
in which C is the concentration, in mg per mL, of USP Cefotetan RS in the Standard preparation; P is the designated potency, in µg of cefotetan (C17H17N7O8S4) per mg, of USP Cefotetan RS; M is the weight, in mg, of Cefotetan taken to prepare the Assay preparation; and rU and rS are the cefotetan peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Brian D. Gilbert, Ph.D., Scientist
Expert Committee : (MDANT05) Monograph Development-Antibiotics
USP29–NF24 Page 423
Phone Number : 1-301-816-8223